Company Description
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.
The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome.
The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma.
It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM.
Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Oct 23, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 116 |
| CEO | Adrian H. B. Gottschalk |
Contact Details
Address: 500 Technology Square, Suite 700 Cambridge, Massachusetts 02139 United States | |
| Phone | 617-586-3100 |
| Website | foghorntx.com |
Stock Details
| Ticker Symbol | FHTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001822462 |
| CUSIP Number | 344174107 |
| ISIN Number | US3441741077 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Adrian H. B. Gottschalk | President, Chief Executive Officer and Director |
| Dr. Steven F. Bellon Ph.D. | Chief Scientific Officer |
| Dr. Alfonso Quintas Cardama M.D. | Chief Medical Officer |
| Dr. Gerald R. Crabtree M.d. | Founder and Member of Scientific Advisory Board |
| Stephen J. DiPalma | Treasurer and Interim Chief Financial Officer |
| Karin Hellsvik | Vice President, Corporate Affairs and Investor Relations |
| Michael J. LaCascia | Chief Legal Officer |
| Saurabh Sewak Ph.D. | Vice President of Corporate Development |
| Carlos Costa | Chief People Officer |
| Fanny Cavalie | Chief Strategy and Business Operations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 6, 2024 | 8-K | Current Report |
| May 6, 2024 | 10-Q | Quarterly Report |
| May 6, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 6, 2024 | 8-K | Current Report |
| May 3, 2024 | ARS | Filing |
| May 3, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 3, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2024 | 8-K | Current Report |
| Apr 9, 2024 | 8-K | Current Report |
| Mar 7, 2024 | 8-K | Current Report |